Treatment of advanced melanoma with laser immunotherapy and ipilimumab |
| |
| Authors: | Mark F. Naylor Feifan Zhou Brian V. Geister Robert E. Nordquist Xiaosong Li Wei R. Chen |
| |
| Affiliation: | 1. Baylor Scott & White Healthcare, Waco, Texas, USA;2. 405–974‐5147;3. Biophotonics Research Laboratory, Center for Interdisciplinary Biomedical Education and Research, University of Central Oklahoma, Edmond, Oklahoma, USA;4. INTEGRIS Cancer Institute, Oklahoma City, USA;5. Immunophotonics Inc., St. Louis, Missouri, USA;6. 405–974‐5147;7. Department of Oncology, the First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China |
| |
| Abstract: | Immunotherapy has become a promising modality for melanoma, especially using checkpoint inhibitors, which revive suppressed T cells against the cancer. Such inhibitors should work better when combined with other treatments which could increase the number and quality of anti‐tumor T cells. We treated one patient with advanced (stage IV) melanoma, using the combination of laser immunotherapy (LIT), a novel immunological approach for metastatic cancers that has been shown to stimulate adaptive immunity, and ipilimumab. The patient was treated with LIT, followed with one course of ipilimumab 3 months after the beginning of LIT. After LIT treatment, all treated cutaneous melanoma in head and neck cleared completely. After the application of ipilimumab, all the tumor nodules in the lungs decreased. The patient had remained tumor free for one year. While anecdotal, the responses seen in this patient support the hypothesis that laser immunotherapy increases the number and quality of anti‐tumor T cells so that ipilimumab and other checkpoint inhibitors are more effective in enhancing the therapeutic effects. Picture : Schematic of treatment using laser immunotherapy and ipilimumab on a stage IV melanoma patient. |
| |
| Keywords: | Immunotherapy checkpoint inhibitor metastatic melanoma ipilimumab laser immunotherapy |
|
|
